Cuixia Liu

Cuixia Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Cancer Science
Verified
Journal Article
Open access
HHHexu Han
Hexu Han
WZWei Zhu
Wei Zhu
TLTing Lin
Ting Lin
CLCuixia Liu
Cuixia Liu
HZHengyong Zhai
Hengyong Zhai
Although angiogenesis is a critical event in hepatocellular carcinoma (HCC), and this process provides the tumor with sufficient oxygen and nutrients, the precise molecular mechanism by which it occurs is not fully understood. NEDD4 binding protein 3 (N4BP3) was identified in this study as a novel pro‐angiogenic factor in HCC cell lines and tissues. We discovered that N4BP3 was significantly expressed in HCC and that its level of expression was positively correlated with the density of tumor microvessels in HCC tissues. Cell biology experiments have shown that N4BP3 knockdown in HCC cells significantly inhibits the formation of complete tubular structures by HUVECs in vitro and HCC angiogenesis in vivo. In HCC cells, overexpression of N4BP3 has the opposite effects. Further cell and molecular biology experiments have revealed that N4BP3 interacts with KAT2B (lysine acetyltransferase 2B), increasing signal transducer and activator of transcription 3 (STAT3) expression by regulating the distribution of acetyl‐histone H3 (Lys27) (H3K27ac) in its promoter region. This, in addition, regulates the activity of the STAT3 signaling pathway, which promotes the proliferation of microvessels in HCC and accelerates the malignant process of the tumor. In vivo experiments in nude mice have confirmed our findings, and also suggested that N4BP3 could be a potential target for the treatment of HCC in combination with sorafenib.

17 June 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JWJianing Wang
Jianing Wang
YLYujun Liu
Yujun Liu
WJWenliang Jiang
Wenliang Jiang
DZDongli Zhang
Dongli Zhang
CCChao Cheng
Chao Cheng
HWHonggang Wang
Honggang Wang
Background: Accurate prognostic stratification remains challenging in colorectal cancer (CRC) patients after curative resection. The Systemic Inflammation Grade (SIG), integrating neutrophil-to-lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS), was proposed as a composite marker to refine risk assessment.Methods: This retrospective study analyzed 263 CRC patients undergoing R0 resection (2015–2019). Preoperative NLR and mGPS were calculated, and SIG was categorized into low (0), medium (1), and high (≥2) groups. Associations between SIG and clinicopathological variables, chemotherapy compliance, and overall survival (OS) were evaluated using ROC analysis, Kaplan-Meier curves, and Cox regression. Subgroup analyses stratified by tumor location (colon vs. rectum) were performed to assess prognostic heterogeneity.Results: Higher SIG scores correlated with elevated CEA (P=0.002), advanced TNM stage (P=0.001), and reduced chemotherapy compliance (64.0% non-compliant patients had SIG≥2, P<0.001). Multivariate analysis identified SIG (HR=2.24, P<0.001), CEA, tumor differentiation, and TNM stage as independent prognostic factors. SIG demonstrated superior prognostic accuracy (AUC=0.785) compared to NLR (0.713), mGPS (0.673), and TNM staging (0.675). Kaplan-Meier analysis revealed significant survival differences across SIG groups (5-year OS: 90.9% vs. 76.4% vs. 37.0%, P<0.001) and additional stratification within TNM stages. Subgroup analysis showed consistent prognostic efficacy of SIG in both colon and rectal cancers, with no significant interaction between SIG and tumor location (P=0.309).Conclusions: SIG outperforms existing biomarkers and complements TNM staging by capturing systemic inflammation-driven risk heterogeneity. Its prognostic consistency across colon and rectal cancers supports its utility as a universal tool for postoperative risk stratification, guiding personalized adjuvant therapy and surveillance strategies.

3 July 2026 in European Journal of Nutrition
Verified
Journal Article
Closed access
YLYujun Liu
Yujun Liu
WJWenliang Jiang
Wenliang Jiang
JWJuan Wang
Juan Wang
SCShaoqi Cheng
Shaoqi Cheng
CCChao Cheng
Chao Cheng
HWHonggang Wang
Honggang Wang